MoneyWorks4Me

Zydus Lifesciences informs about press release

22 Apr 2024 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated April 22, 2024 titled ‘Zydus launches Mirabegron Extended-Release Tablets in the US’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1134.25 -15.75 (-1.37%)
09-Sep-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.00
Dr. Reddys Labs. 1140.75
Cipla 1374.00
Lupin 2102.30
Zydus Lifesciences 1134.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: